On August 31, 2022 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that it will participate in three upcoming investor conferences (Press release, Arvinas, AUG 31, 2022, View Source [SID1234618804]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 17th Annual BioPharma Conference: Thursday, September 8 at 1:00 p.m. ET. Sean Cassidy, chief financial officer, and Ron Peck, M.D., chief medical officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

2022 Wells Fargo Healthcare Conference: Friday, September 9 at 9:45 a.m. ET. Sean Cassidy, chief financial officer, and Ron Peck, M.D., chief medical officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

Morgan Stanley 20th Annual Global Healthcare Conference: Monday, September 12 at 11:05 a.m. ET. Ian Taylor, Ph.D., chief scientific officer, and Randy Teel, senior vice president, corporate and business development, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.